The research study titled ‘Global Medical Grade Tubing Market’ is aimed at assessing the market potential of various applications in the overall medical grade tubing market. The research report constitutes an in-depth study of the global medical grade tubing market, including a thorough analysis of revenues generated by companies involved in the development of medical grade tubing.  Based on the product launches, approvals, and ongoing strategic collaborations, as well as business expansion, the market size and potential for the forecast period 2021-2030 have been estimated. The report focuses on the assessment of the market by product, material, application, end market, and region.

Peptides are a selective, efficacious, and unique class of molecules that bind to specific cell surface receptors, triggering intracellular effects. They are short chains of amino acids linked by a peptide bond. Although they are molecularly poised between small molecules and proteins, peptides have distinctive therapeutic and biochemical properties. They represent an attractive first step in developing novel therapeutics across different areas, including oncology, metabolic, cardiovascular, infectious, endocrine, neurology, and other disorders. For decades, researchers have endeavored to comprehend intracellular protein-protein interactions (PPIs) as they play a critical role in the pathogenesis of numerous disease states. The development of constrained peptides exhibits an emerging approach that addresses challenging PPIs.

The study defines cancer microbiome as the aggregate of microorganisms living in or on the human body along with their genomes that are influencing cancer manifestation and progression. Cancer microbiome sequencing has increasingly become an area of interest for the research community, which has the potential to revolutionize cancer care, largely due to studies that have significantly correlated the microbiome’s involvement in cancer manifestation. This study aims at deciphering the potential of the cancer microbiome sequencing and its larger role in bolstering the current era of precision medicine.

The prevalence of several chronic diseases worldwide and the launch of sophisticated technologies and treatments have contributed to a rapid increase in healthcare expenses. Additionally, patients nowadays expect high-quality care at an affordable cost. Thus, it has become imperative for players in the healthcare industry to reduce the cost of their healthcare services while providing high-quality care to patients. Efficient healthcare logistics services provide a remarkable opportunity for controlling healthcare costs through the implementation of best practices.

Immunotherapy, a non-traditional treatment, has become a prominent approach for treating many diseases, especially cancer, because it provides superior efficacy and safety. During this era of precision medicine and effective immunotherapies, the necessity for rapid and efficient antineoplastic development has never been greater. Biologics or biologic drugs are derived from living organisms and have proved to be a cure for several chronic conditions that were previously considered untreatable.

AI in healthcare has enormous and far-reaching potential, from mobile training solutions to drug discovery, which fall within the realm of machine learning. Artificial intelligence (AI) in healthcare refers to the use of complex algorithms that are supposed to perform certain tasks automatically. When researchers, doctors, and scientists input data into computers, newly developed algorithms can review, interpret, and even suggest solutions to complex medical problems.

全球疫情有明显抬头趋势，国内动态清零政策短期内不会变化。进入2022年3月以来，全球确诊人数增速有明显抬头趋势，Omicron仍然为主要流行株。国内各地散点疫情也呈爆发状态，截至3月15日，国内单日新增确诊病例1860人，为武汉疫情以来国内疫情形势最严峻的一次。从政策上看，国内防疫政策总基调不变，坚持“外防输入、内防反弹”总策略、“动态清零”总方针。监测模式变为推进“抗原筛查、核酸诊断” ，在核酸检测基础上增加抗原检测作为补充。

创新药板块受多方面因素影响，目前整体估值已基本回落至疫情前水平，从中长期角度看，我们认为板块估 值已经回归理性，当前时间节点具有较好的中长期布局价值。 随着多项创新药相关的注册审批、医保准入、终端推广等政策发布，中国创新药行业发展已进入规范化发展 新阶段。中国创新药行业持续快速发展，部分商业化品种具备重磅品种的潜力，随着进入商业化阶段的品种 持续增多，就创新药企业而言，结合自身产品特点，采取符合企业自身资源禀赋的创新药策略有机会在商业 化阶段获得更大的成功。

2022 年3 月22 日，为了指导各地更好地建设方舱医院，国家卫健委以国务院 联防联控机制综合组名义印发了《方舱医院设置管理规范》（下文称《规范》）， 从方舱医院的选址、三区两通道的设置、病区的设置和管理、医护人员按照床 位的比例如何配置、信息化手段、信息的传递、污水污物的处理、隔离管理的 患者生活保障，以及整个方舱医院的安全保障等方方面面，从各个细节做了非 常详细的指导。今年3 月份以来新冠确诊数趋高，此轮疫情新冠病毒病原体多 以奥密克戎毒株为主，传染性较强，致死率较低，患者的症状非常隐匿，表现 总体偏轻，以轻型和无症状感染者居多，占比高达90%以上。这部分轻型患者 和无症状感染者的诊疗需要在具备一定医疗条件的集中隔离场所进行，以观察 病情变化和对症处理为主。但是由于需要隔离的人员数量在快速增加，在这种 情况下，能满足隔离和治疗需求的定点医院、隔离点的供需矛盾非常突出，因 此方舱医院的建设必要性大幅提升。

盘高成长，建议自下而上精选个股。根据国内疫情防控趋势及2022Q1 业绩前瞻分析， 2022 年建议紧抱“新冠相关需求提升”+“卡脖子技术进口替代”，两条投资主线。